Asset
Zanubrutinib
BeOne Medicines Ltd. American Depositary Shares
Revenue
| Period | Revenue |
|---|---|
| Q2 2026 | $1.2B |
| Q2 2025 | $949.8M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive.
Clinical trials (44)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03561298 | phase1 | completed | 2018-06-07 | 2018-06-07 | BeiGene | A Pharmacokinetic Study to Assess Drug-drug Interaction Between Zanubrutinib and a Cocktail of Substrates in Healthy Subjects |
| NCT03332017 | phase2 | completed | 2017-11-14 | 2021-10-08 | BeiGene | A Study Comparing Obinutuzumab and BGB-3111 Versus Obinutuzumab Alone in Treating R/R Follicular Lymphoma |
| NCT03336333 | phase3 | active_not_recruiting | 2017-10-31 | 2021-05-07 | BeiGene | A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL |
| NCT03734016 | phase3 | completed | 2018-11-01 | 2022-08-08 | BeiGene | A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia |
| NCT05100862 | phase3 | active_not_recruiting | 2022-03-10 | 2028-07-01 | BeOne Medicines | A Study of Zanubrutinib Plus Anti-CD20 Versus Lenalidomide Plus Rituximab in Participants With Relapsed/Refractory Follicular or Marginal Zone Lymphoma |
FDA applications (2)
| Application | Type | Applicant |
|---|---|---|
| NDA 213217 | NDA | BEONE MEDICINES USA INC |
| NDA 218785 | NDA | BEONE MEDICINES USA INC |
Marketed products (3)
- BRUKINSA
- BRUKINSA
- BRUKINSA